Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
{{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}}
{{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | |D01| | | | | |D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Adenocarcinoma and poorly differntiated carcinoma'''|D03='''Neuroendocrine carcinoma'''}}
{{familytree | |D01| | | | | |D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}}
{{familytree | | |!| | | | | | | | |!| | | | |!| }}
{{familytree | | |!| | | | | | | | |!| | | | |!| }}
{{familytree | | |E01| | | | | |E02 | | | |E03| |E01=Additional tests specific to location of metastasis|E02=Gender specific tests|E03=• Octreoscan<br> • Plasma chromogranin A}}
{{familytree | | |E01| | | | | |E02 | | | |E03| |E01=Additional tests specific to location of metastasis|E02=• Octreoscan<br> • Plasma chromogranin A|E03=Gender specific tests}}
{{familytree | |,|-|+|-|.| | |!| | | | | | | | }}
{{familytree | |,|-|+|-|.| | |!| | | | | | | | }}
{{familytree |F01| |F02| |F03 | |!| | | | | | |F01=bone|F02=Ing|F03=Supra}}
{{familytree |F01| |F02| |F03 | |!| | | | | | |F01=bone|F02=Ing|F03=Supra}}
{{familytree | | | | | | | |,|-|^|-|.| | | | | | }}
{{familytree | | | | | |boxstyle=text-align: left; |G01| | | |G02| | | | |G01='''Male'''<br> • PSA <br> • aFP <br> • BHCG|G02='''Female'''<br> • Mammography <br> • Ultrasound or pelvic CT}}
{{familytree/end}}
{{familytree/end}}

Revision as of 18:59, 10 October 2018

 
 
 
 
 
 
 
 
Tumor of unknown primary origin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Full medical history and physical exam
• Basic blood and bichemical analysis
• CT scan of chest, abdomen, and pelvis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathologic examination
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Squamous cell carcinoma
 
 
 
 
 
Neuroendocrine carcinoma
 
 
 
Adenocarcinoma and poorly differntiated carcinoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional tests specific to location of metastasis
 
 
 
 
 
• Octreoscan
• Plasma chromogranin A
 
 
 
Gender specific tests
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
bone
 
Ing
 
Supra